Need Help?

Canadian Prostate Cancer Genome Network

Over 5 years, CPC-GENE will sequence the genomes of 350 intermediate risk prostate cancers to identify genetic signatures that differ in cancers that responded well to treatment compared with those that did not. CPC-GENE will also sequence multiple regions of prostate cancer from the same gland to determine if and how the genetic make-up of prostate cancer varies within an individual man’s prostate

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001001094 Illumina HiSeq 2500 247
EGAD00001001115 Illumina HiSeq 2500 54
EGAD00001003139 262
EGAD00001003706 Illumina HiSeq 2000 Illumina HiSeq 2500 unspecified 616
EGAD00001003756 Illumina HiSeq 2000 98
EGAD00001003761 Illumina HiSeq 2000 Illumina HiSeq 2500 unspecified 617
EGAD00001003909 HiSeq X Ten Illumina HiSeq 2000 Illumina HiSeq 2500 unspecified 610
EGAD00001003957 Illumina HiSeq 2000 Illumina HiSeq 2500 unspecified 23
EGAD00001003975 HiSeq X Ten Illumina HiSeq 2500 unspecified 128
EGAD00001004061 404
EGAD00001004072 293
EGAD00001004073 292
EGAD00001004400 538
EGAD00001004401 562
EGAD00001004402 580
EGAD00001004403 538
EGAD00001004404 562
EGAD00001004405 580
EGAD00001004424 Illumina HiSeq 2000 148
EGAD00001004431 40
EGAD00001004432 40
EGAD00001004433 40
EGAD00001004434 40
EGAD00001004440 40
EGAD00001004441 40
EGAD00001004442 40
EGAD00001004443 40
EGAD00001004875 56
EGAD00010001218 Affymetrix OncoScan FFPE Express 502
EGAD00010001414 Affymetrix OncoScan FFPE Express -
EGAD00010001519 Affymetrix OncoScan FFPE Express 110
EGAD00010001703 144
Publications Citations
Genomic hallmarks of localized, non-indolent prostate cancer.
Nature 541: 2017 359-364
313
Molecular Hallmarks of Multiparametric Magnetic Resonance Imaging Visibility in Prostate Cancer.
Eur Urol 76: 2019 18-23
30
The Proteogenomic Landscape of Curable Prostate Cancer.
Cancer Cell 35: 2019 414-427.e6
104
Genome-wide germline correlates of the epigenetic landscape of prostate cancer.
Nat Med 25: 2019 1615-1626
34
Quantifying the influence of mutation detection on tumour subclonal reconstruction.
Nat Commun 11: 2020 6247
9
CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer.
Nat Commun 12: 2021 1781
23
Reference-free transcriptome signatures for prostate cancer prognosis.
BMC Cancer 21: 2021 394
6
Multiplexed functional genomic analysis of 5' untranslated region mutations across the spectrum of prostate cancer.
Nat Commun 12: 2021 4217
19
Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse.
Nat Commun 12: 2021 6248
12
The telomere length landscape of prostate cancer.
Nat Commun 12: 2021 6893
7
Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways.
Nat Commun 13: 2022 2669
59
Starfish infers signatures of complex genomic rearrangements across human cancers.
Nat Cancer 3: 2022 1247-1259
16
The cell-free DNA methylome captures distinctions between localized and metastatic prostate tumors.
Nat Commun 13: 2022 6467
19
A polygenic two-hit hypothesis for prostate cancer.
J Natl Cancer Inst 115: 2023 468-472
2
The Genomic and Epigenomic Landscape of Double-Negative Metastatic Prostate Cancer.
Cancer Res 83: 2023 2763-2774
7
Global impact of somatic structural variation on the cancer proteome.
Nat Commun 14: 2023 5637
6